Latest news with #Hingham
Yahoo
22-07-2025
- Business
- Yahoo
Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales
Company Continues to Strengthen Organizational Infrastructure with Success-Driven Medical Device Veteran Christina Bailey, VP of Sales, Microbot Medical HINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales. A two-time U.S. Olympian with 20 years of medical device sales experience, Ms. Bailey has successfully led commercial teams to achieve sales goals. She will report directly to Harel Gadot, the Company's CEO, President and Chairman. Ms. Bailey has held a variety of sales leadership roles. She has worked with notable companies like Boston Scientific, Abbott, Stryker and Intuitive Surgical that have equipped her with the insights necessary to drive growth and innovation. As the Vice President of US Sales at Endologix, her leadership in building and scaling the sales team while achieving sales milestones demonstrate her capability to lead crucial product launches. Ms. Bailey serves as a Board Member for USA Hockey. As a member of the U.S.A. Women's Hockey Team, she won a gold medal at the 1998 Winter Olympics held in Nagano, Japan. 'Christina is a sales leader with a track record of building and working within high-performing teams across her professional and Olympic careers,' commented Mr. Gadot. 'We believe her leadership will strengthen our commercial efforts as she begins establishing an experienced and mission-driven sales team to support our anticipated launch of LIBERTY.' LIBERTY is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the U.S. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. Further information about Microbot Medical® is available at Safe Harbor Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as 'contemplates,' 'continues,' 'could,' 'forecasts,' 'intends,' 'may,' 'might,' 'possible,' 'potential,' 'predicts,' 'projects,' 'should,' 'would,' 'will,' 'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates' and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading 'Risk Factors' in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law. Investor Contact: IR@ A photo accompanying this announcement is available at in to access your portfolio
Yahoo
11-07-2025
- Business
- Yahoo
Hingham Savings: Q2 Earnings Snapshot
HINGHAM, Mass. (AP) — HINGHAM, Mass. (AP) — Hingham Institution for Savings (HIFS) on Friday reported net income of $9.4 million in its second quarter. The bank, based in Hingham, Massachusetts, said it had earnings of $4.28 per share. Earnings, adjusted for non-recurring gains, were $3.39 per share. The community bank posted revenue of $54.1 million in the period. Its revenue net of interest expense was $20.8 million, exceeding Street forecasts. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on HIFS at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
27-06-2025
- Sport
- CBS News
South Shore Sports Center in Hingham, Massachusetts destroyed in fire
The South Shore Sports Center, a popular complex for the community in Hingham, Massachusetts, was destroyed in a fire overnight. Flames broke out in the facility on Recreation Park Drive just after 11 p.m. Thursday and quickly tore through the roof. 3rd Alarm Hingham Ma. 50 Recreation Park Drive. (2) — Stewie (@MassFirePics) June 27, 2025 Firefighters found heavy flames in the kitchen and dining area. They spent hours trying to save the building, but Hingham Deputy Fire Chief David Levenson said the building is a total loss. The sports complex is well known on the South Shore for its sports leagues and birthday parties. "It's been around for 25 years or more (for) soccer, basketball, baseball. Everything went on here. It's going to be a loss for the community if they're unable to rebuild," Levenson told reporters Friday. The building is so damaged investigators can't get inside yet to find out where and how the fire started. Levenson said the next step will be the demolition of the complex.
Globe and Mail
09-06-2025
- Business
- Globe and Mail
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its commercial team in preparation for the anticipated U.S. launch of the LIBERTY System, which is projected during the third quarter of 2025. The Company remains actively engaged with the U.S. Food and Drug Administration (FDA), with a 510(k) decision now expected during the third quarter of this year. This updated FDA decision timeline remains within the FDA's original scheduled review window and is not expected to affect the Company's planned launch upon clearance. 'Our recent interactions with the FDA have been productive, and we remain confident in the process and outcome,' said Harel Gadot, Chairman, CEO & President. 'We continue to operate with full momentum and position the Company for an anticipated launch during the third quarter of this year, which includes the continued build out of our commercial infrastructure and preparing the organization to deliver on our strategy.' As part of the Company's ongoing launch preparation, it recently expanded its commercial team with the addition of Michael Lytle as the head of Sales Operations & Analytics. Mr. Lytle brings deep experience in sales support, data analysis, and operational excellence. He is expected to play a key role in shaping market intelligence tools and processes to optimize the sales cycle and drive strategic growth. Prior to joining Microbot, Mr. Lytle held increasing leadership roles at ZOLL Cardiac Management Solutions (CMS), a division of ZOLL Medical Corporation, where he supported the rollout of innovative cardiac care technologies. 'We believe that Michael's addition will strengthen our launch readiness plans, and that his expertise will help us target the right markets, allocate resources effectively, and accelerate commercial execution,' concluded Mr. Gadot. The LIBERTY System is currently under FDA review, is not available for sales in the US, and clearance is not guaranteed. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. Further information about Microbot Medical® is available at Safe Harbor Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as 'will,' 'believes,' 'plans,' 'anticipates,' 'expects' and 'estimates') should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading 'Risk Factors' in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law
Boston Globe
09-06-2025
- Sport
- Boston Globe
Behind standout Bella Camacho, No. 2 Wayland girls' tennis soars into Division 2 semifinals
Elena Tan (6-0, 6-0) and Olivia Todd (6-0, 6-0) also coasted at singles for Wayland (13-5). Arya Samaratunga and Yumi Niimi earned a 6-3, 6-1 victory at No. 1 doubles, and Emi Niimi and Ava Knourenko grinded out a 6-3, 6-2 win at No. 2 doubles. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up The Warriors, who fell in the quarterfinals last year, were delighted to break through. Advertisement 'I'm just glad that all the work they've put in from Day 1, talking about getting to the Final Four and talking about winning, it's within their grasp,' said Wayland coach Jason Tassinari. 'I'm proud of them, and very thankful that we have more time with this great team.' While Duxbury's season ends at 16-5, Wayland gets ready to face No. 3 Notre Dame (Hingham) in the semifinals (TBA). Hingham 5, Amherst-Pelham 0 — In their quarterfinal sweep of No. 5 Amherst-Pelham (14-4), the fourth-seeded Harborwomen (20-1) took each match in straight sets, led by the second doubles duo of Cassie McCabe and Maddie Cusak with a 6-0, 6-0 win. Advertisement In singles, Sam Rudduick (6-2, 6-1), Sanya Khadivi (6-4, 6-3), and Hannah Mello (6-1, 6-1) rolled, and the first doubles pairing of Sammy Price and Gabi Magner won, 6-0, 6-1. Hingham will battle top-seeded Longmeadow in the semifinals (TBA). Division 4 State Lynnfield 5, Nantucket 0 — Paige Martino, Lily Alves, and Kami Khiat all won in straight sets in a quarterfinals victory for the top-seeded Pioneers (18-2) against No. 8 Nantucket (10-7). Lynnfield advances to play No. 4 Hamilton-Wenham (16-2) in the semifinals Wednesday (TBA). Boys' tennis Division 4 State Lynnfield 4, Mystic Valley 1 — At second singles, Shlok Kudrimoti came back after losing twice to his opponent in previous meetings, yet secured the third point for the second-seeded Pioneers (16-6) in a quarterfinals win over No. 7 Mystic Valley (12-10). Lenny Rowe and Cam Kerry contributed. Trevor Hass can be reached at
